This week PharmaShots’ news was all about the updates on M&A, Pharma, Clinical Trials, Regulatory & MedTech. Check out our full report below:

Eli Lilly and Boehringer Ingelheim Reveal Results from the P-III (EMPACT-MI) Study of Jardiance to Prevent the Risk of Heart Failure and Death Post Heart Attack

Read More: Eli Lilly & Boehringer Ingelheim                                                        

Novartis Reveals the P-IIIb (V-INITIATE) Trial Results of Leqvio for Treating Atherosclerotic Cardiovascular Disease (ASCVD)

Read More: Novartis                                                                                                 

BMS Reveals Pooled Interim Results from a Series of P-III (EMERGENT) Studies Evaluating KarXT for Schizophrenia at the SIRS 2024

Read More: BMS                                                                                                       

BMS Features the P-I/II Study Results of Krazati in Addition with Cetuximab for the Treatment of Locally Advanced or Metastatic Colorectal Cancer at the AACR 2024

Read More: BMS                                                                                                   

Pfizer Reveals the P-III Study Data of Abrysvo for Increased Risk for RSV Disease

Read More: Pfizer                                                                                    

Rapt Therapeutics Highlights Results from the P-II Study of Tivumecirnon in Combination with Keytruda for Treating Head and Neck Cancer 

Read More: Rapt Therapeutics                                                                     

Monopar Therapeutics Commences the P-I Trial of MNPR-101-Zr for Treating Advanced Cancer

Read More: Monopar Therapeutics                                                                     

Teva Reports the P-III Study Data of Ajovy (fremanezumab) to Prevent Migraine in Chinese Patients

Read More: Teva                                                                                                  

Boundless Bio Reports First Patient Dosing with BBI-825 in the P-I/II Study for Cancer Treatment

Read More: Boundless Bio                                                                                       

Enliven Therapeutics Reveals the PoC Results from the P-I Clinical Evaluation of ELVN-001 for the Treatment of Chronic Myeloid Leukemia

Read More: Enliven Therapeutics                                                                     

AstraZeneca and Daiichi Sankyo’s Enhertu Gains the US FDA’s Accelerated Approval to Treat Metastatic HER2-Positive Solid Tumors

Read More: AstraZeneca & Daiichi                                                                      

The US FDA Grants FTD to PureTech’s LYT-200 for the Treatment of Head and Neck Cancers

Read More: PureTech                                                                                           

Candel Therapeutics’ CAN-2409 Obtains the US FDA’s Orphan Drug Designation to Treat Pancreatic Cancer

Read More: Candel Therapeutics                                                                          

Boston Scientific Reports the Commencement of NAVIGATE-PF Study Evaluating Farawave Nav Pulsed Field Ablation Catheter and Faraview Software Module

Read More: Boston Scientific                                                                                   

HeartBeam Highligts Data from the Study of Using Artificial Intelligence for Detecting Arrhythmias 

Read More: HeartBeam                                                                                       

Roche’s Ventana HER2 (4B5) Test Gains CE Mark for HER2-Low Metastatic Breast Cancer

Read More: Roche                                                                                            

The US FDA Grants Breakthrough Device Designation to Roche’s Elecsys pTau217 Assay for Diagnosing Alzheimer's Disease

Read More: Roche                                                                                          

The US FDA Grants Breakthrough Device Designation to Simpson Interventions’ Acolyte Image Guided Crossing and Re-Entry Catheter System

Read More: Simpson                 

Henlius and Organon Reveal Results from the P-III Study of HLX14, Biosimilar Candidate of Denosumab

Read More: Henlius & Organon                                                                                

Coherus BioSciences Highlights the Preclinical Data of CHS-1000 for Solid Tumors at the AACR 2024

Read More: Coherus BioSciences                                                                            

Merus Features the Zenocutuzumab’s Preclinical Results for Cancer Treatment at the AACR 2024

Read More: Merus                                                                                                     

Nucleai and GoPath Diagnostics Collaborate on AI-Based Digital Pathology Solutions for Clinical Research and Diagnosis

Read More: Nucleai & GoPath Diagnostics                                                       

Transcenta Collaborates with Agilent Technologies on Claudin18.2 Companion Diagnostic to Support the P-III Study of Osemitamab

Read More: Transcenta & Agilent Technologies                                       

Bayer Partners with Google Cloud on AI-Based Solutions for Radiologists

Read More: Bayer & Google Cloud                                                           

Merck Animal Health Launches Flocksecure Poultry Health Portal

Read More: Merck Animal Health                                                                

NeuroSense and Lonza Join Forces on Exosome-based Biomarkers for the Diagnosis and Treatment of Neurodegenerative Disease 

Read More: NeuroSense & Lonzav                                                                 

Rallybio and Johnson & Johnson Collaborate to Develop Therapies for Preventing Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

Read More: Rallybio & Johnson & Johnson                                                          

Arvinas and Novartis Join Forces to Develop and Commercialize ARV-766 for Treating Prostate Cancer

Read More: Arvinas & Novartis                                                                                 

Harmony Biosciences and Bioprojet Join Forces to Develop TPM-1116 for Treating Narcolepsy and Other Sleep/Wake Disorders

Read More: Harmony Biosciences & Bioprojet                           

For an Aggregate of ~$4.9B, Vertex to Acquire Alpine Immune Sciences

Read More: Vertex & Alpine Immune Sciences                                                   

Related Post:- PharmaShots Weekly Snapshots (April 01 – April 05, 2024)